Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 05-Oct-21 5:36 PM View:  | Pieper Steven Chief Financial Officer | Xeris Pharmaceuticals Inc (XERS) | 05-Oct-21 | Disposition | 158,108 | -- | -- | (100%) 158.11K to 0 | |
| 05-Oct-21 5:33 PM View: | Johnson Kenneth Erland See Remarks | Xeris Pharmaceuticals Inc (XERS) | 05-Oct-21 | Disposition | 89,583 | -- | -- | (100%) 89.58K to 0 | |
| 05-Oct-21 5:34 PM View: | Hecht Beth See Remarks | Xeris Pharmaceuticals Inc (XERS) | 05-Oct-21 | Disposition | 206,366 | -- | -- | (100%) 206.37K to 0 | |
| 05-Oct-21 5:37 PM View: | Schmid John P. Director | Xeris Pharmaceuticals Inc (XERS) | 05-Oct-21 | Disposition | 5,659 | -- | -- | (100%) 5.66K to 0 | |
| 05-Oct-21 5:34 PM View: | Prestrelski Steven Chief Scientific Officer | Xeris Pharmaceuticals Inc (XERS) | 05-Oct-21 | Disposition | 494,780 | -- | -- | (100%) 494.78K to 0 | |
| 05-Oct-21 5:36 PM View: | Edick Paul R Chief Executive Officer Director | Xeris Pharmaceuticals Inc (XERS) | 05-Oct-21 | Disposition | 608,064 | -- | -- | (98%) 621.49K to 13.43K | |
| 05-Oct-21 5:32 PM View: | Shannon John Patrick Jr See Remarks | Xeris Pharmaceuticals Inc (XERS) | 05-Oct-21 | Disposition | 263,829 | -- | -- | (100%) 263.83K to 0 | |
| 05-Oct-21 5:36 PM View: | Edick Paul R Chief Executive Officer Director | Xeris Pharmaceuticals Inc (XERS) | 05-Oct-21 | Disposition | 13,430 | -- | -- | (100%) 13.43K to 0 | |
| 29-Jul-21 6:06 PM View: | Pieper Steven See Remarks | Xeris Pharmaceuticals Inc (XERS) | 28-Jul-21 | Grant | 100,000 | -- | -- | 170% 58.86K to 158.86K | |
| 13-Apr-21 5:06 PM View: | Prestrelski Steven Chief Scientific Officer | Xeris Pharmaceuticals Inc (XERS) | 12-Apr-21 | Market Sale (Planned) | 10,000 | $4.07 | $40,725.00 | (2%) 506.82K to 496.82K | 3% |
| 01-Feb-21 4:12 PM View: | Johnson Kenneth Erland See Remarks | Xeris Pharmaceuticals Inc (XERS) | 29-Jan-21 | Grant | 65,000 | -- | -- | 242% 26.89K to 91.89K | |
| 01-Feb-21 4:06 PM View: | Deutsch Barry M. See Remarks | Xeris Pharmaceuticals Inc (XERS) | 29-Jan-21 | Grant | 115,000 | -- | -- | 124% 93.09K to 208.09K | |
| 01-Feb-21 4:11 PM View: | Hecht Beth See Remarks | Xeris Pharmaceuticals Inc (XERS) | 29-Jan-21 | Grant | 150,000 | -- | -- | 247% 60.81K to 210.81K | |
| 01-Feb-21 4:22 PM View: | Edick Paul R See Remarks Director | Xeris Pharmaceuticals Inc (XERS) | 29-Jan-21 | Grant | 225,000 | -- | -- | 53% 424.56K to 649.56K | |
| 01-Feb-21 4:17 PM View: | Prestrelski Steven Chief Scientific Officer | Xeris Pharmaceuticals Inc (XERS) | 29-Jan-21 | Grant | 100,000 | -- | -- | 25% 406.82K to 506.82K | |
| 01-Feb-21 4:20 PM View: | Shannon John Patrick Jr See Remarks | Xeris Pharmaceuticals Inc (XERS) | 29-Jan-21 | Grant | 150,000 | -- | -- | 124% 121.22K to 271.22K | |
| 15-Jan-21 4:03 PM View: | Prestrelski Steven Chief Scientific Officer | Xeris Pharmaceuticals Inc (XERS) | 13-Jan-21 | Market Sale (Planned) | 10,000 | $6.01 | $60,058.00 | (2%) 416.82K to 406.82K | 15% |
| 12-Jan-21 4:02 PM View: | Prestrelski Steven Chief Scientific Officer | Xeris Pharmaceuticals Inc (XERS) | 11-Jan-21 | Market Sale (Planned) | 10,000 | $5.72 | $57,244.00 | (2%) 426.82K to 416.82K | 11% |
| 17-Dec-20 4:40 PM View: | Prestrelski Steven Chief Scientific Officer | Xeris Pharmaceuticals Inc (XERS) | 16-Dec-20 | Gift | 10,000 | -- | -- | (2%) 436.82K to 426.82K | |
| 10-Dec-20 4:52 PM View: | Edick Paul R See Remarks Director | Xeris Pharmaceuticals Inc (XERS) | 09-Dec-20 | Market Purchase | 10,000 | $4.06 | $40,551.00 | 2% 414.56K to 424.56K | 25% |
| 15-Jul-20 4:52 PM View: | Johnson Kenneth Erland See Remarks | Xeris Pharmaceuticals Inc (XERS) | 30-Jun-20 | Grant | 775 | $2.26 | $1,751.50 | 3% 26.11K to 26.89K | |
| 15-Jul-20 4:53 PM View: | Deutsch Barry M. See Remarks | Xeris Pharmaceuticals Inc (XERS) | 30-Jun-20 | Grant | 3,731 | $2.26 | $8,432.06 | 4% 89.36K to 93.09K | |
| 15-Jul-20 4:54 PM View: | Hecht Beth See Remarks | Xeris Pharmaceuticals Inc (XERS) | 30-Jun-20 | Grant | 3,731 | $2.26 | $8,432.06 | 7% 57.08K to 60.81K | |
| 15-Jul-20 4:53 PM View: | Shannon John Patrick Jr See Remarks | Xeris Pharmaceuticals Inc (XERS) | 30-Jun-20 | Grant | 3,731 | $2.26 | $8,432.06 | 3% 117.49K to 121.22K | |
| 14-May-20 4:30 PM View: | Shannon John Patrick Jr See Remarks | Xeris Pharmaceuticals Inc (XERS) | 13-May-20 | Market Purchase | 22,000 | $3.55 | $77,994.40 | 23% 95.49K to 117.49K | 43% |
| 11-May-20 6:17 PM View: | Shannon John Patrick Jr See Remarks | Xeris Pharmaceuticals Inc (XERS) | 08-May-20 | Market Purchase | 7,886 | $3.20 | $25,219.40 | 9% 87.61K to 95.49K | 59% |
| 11-May-20 5:06 PM View: | Edick Paul R See Remarks Director | Xeris Pharmaceuticals Inc (XERS) | 08-May-20 | Market Purchase | 33,000 | $3.00 | $99,000.00 | 9% 381.56K to 414.56K | 69% |
| 16-Mar-20 4:07 PM View: | Hecht Beth See Remarks | Xeris Pharmaceuticals Inc (XERS) | 13-Mar-20 | Market Purchase | 4,000 | $1.97 | $7,880.00 | 8% 53.08K to 57.08K | 158% |
| 18-Feb-20 5:02 PM View: | Shannon John Patrick Jr See Remarks | Xeris Pharmaceuticals Inc (XERS) | 14-Feb-20 | Market Purchase | 12,048 | $4.15 | $49,999.20 | 114% 10.56K to 22.61K | 22% |
| 18-Feb-20 4:55 PM View: | Deutsch Barry M. See Remarks | Xeris Pharmaceuticals Inc (XERS) | 14-Feb-20 | Market Purchase | 9,639 | $4.15 | $40,001.90 | 32% 29.72K to 39.36K | 22% |
| 18-Feb-20 5:02 PM View: | Edick Paul R See Remarks Director | Xeris Pharmaceuticals Inc (XERS) | 14-Feb-20 | Market Purchase | 20,000 | $4.15 | $83,000.00 | 11% 176.56K to 196.56K | 22% |
| 18-Feb-20 4:59 PM View: | Johnson Kenneth Erland See Remarks | Xeris Pharmaceuticals Inc (XERS) | 14-Feb-20 | Market Purchase | 2,410 | $4.15 | $10,001.50 | 65% 3.71K to 6.12K | 22% |
| 18-Feb-20 5:02 PM View: | Hecht Beth See Remarks | Xeris Pharmaceuticals Inc (XERS) | 14-Feb-20 | Market Purchase | 4,000 | $4.15 | $16,600.00 | 98% 4.08K to 8.08K | 22% |
| 02-Mar-20 4:53 PM View: | Hecht Beth See Remarks | Xeris Pharmaceuticals Inc (XERS) | 31-Jan-20 | Grant | 45,000 | -- | -- | 557% 8.08K to 53.08K | |
| 02-Mar-20 4:53 PM View: | Shannon John Patrick Jr See Remarks | Xeris Pharmaceuticals Inc (XERS) | 31-Jan-20 | Grant | 65,000 | -- | -- | 288% 22.61K to 87.61K | |
| 02-Mar-20 4:52 PM View: | Edick Paul R See Remarks Director | Xeris Pharmaceuticals Inc (XERS) | 31-Jan-20 | Grant | 185,000 | -- | -- | 94% 196.56K to 381.56K | |
| 04-Feb-20 5:00 PM View: | Edick Paul R See Remarks Director | Xeris Pharmaceuticals Inc (XERS) | 31-Jan-20 | Payment of Exercise | 9,801 | $6.37 | $62,432.40 | (5%) 186.37K to 176.56K | 20% |
| 02-Mar-20 4:57 PM View: | Prestrelski Steven Chief Scientific Officer | Xeris Pharmaceuticals Inc (XERS) | 31-Jan-20 | Grant | 15,000 | -- | -- | 4% 421.82K to 436.82K | |
| 02-Mar-20 4:56 PM View: | Johnson Kenneth Erland See Remarks | Xeris Pharmaceuticals Inc (XERS) | 31-Jan-20 | Grant | 20,000 | -- | -- | 327% 6.12K to 26.11K | |
| 02-Mar-20 4:50 PM View: | Deutsch Barry M. See Remarks | Xeris Pharmaceuticals Inc (XERS) | 31-Jan-20 | Grant | 50,000 | -- | -- | 127% 39.36K to 89.36K | |
| 14-Jan-20 4:40 PM View: | Prestrelski Steven Chief Scientific Officer | Xeris Pharmaceuticals Inc (XERS) | 13-Jan-20 | Market Sale (Planned) | 10,000 | $5.50 | $54,992.00 | (2%) 431.82K to 421.82K | 8% |
| 06-Jan-20 6:10 PM View: | Johnson Kenneth Erland See Remarks | Xeris Pharmaceuticals Inc (XERS) | 31-Dec-19 | Grant | 286 | $5.99 | $1,713.14 | 8% 3.42K to 3.71K | |
| 06-Jan-20 6:17 PM View: | Hecht Beth See Remarks | Xeris Pharmaceuticals Inc (XERS) | 31-Dec-19 | Grant | 459 | $5.99 | $2,749.41 | 13% 3.62K to 4.08K | |
| 06-Jan-20 6:09 PM View: | Shannon John Patrick Jr See Remarks | Xeris Pharmaceuticals Inc (XERS) | 31-Dec-19 | Grant | 438 | $5.99 | $2,623.62 | 4% 10.12K to 10.56K | |
| 27-Nov-19 4:43 PM View: | Edick Paul R See Remarks Director | Xeris Pharmaceuticals Inc (XERS) | 25-Nov-19 | Market Purchase | 17,935 | $8.55 | $153,283.00 | 11% 168.43K to 186.37K | (41%) |
| 20-Nov-19 4:44 PM View: | Prestrelski Steven Chief Scientific Officer | Xeris Pharmaceuticals Inc (XERS) | 19-Nov-19 | Gift | 17,500 | -- | -- | (4%) 449.32K to 431.82K | |
| 16-Oct-19 4:27 PM View: | Prestrelski Steven Chief Scientific Officer | Xeris Pharmaceuticals Inc (XERS) | 11-Oct-19 | Market Sale (Planned) | 10,000 | $7.97 | $79,746.00 | (2%) 459.32K to 449.32K | 37% |
| 16-Oct-19 4:27 PM View: | Prestrelski Steven Chief Scientific Officer | Xeris Pharmaceuticals Inc (XERS) | 11-Jul-19 | Market Sale (Planned) | 10,000 | $12.04 | $120,395.00 | (2%) 469.32K to 459.32K | 58% |
| 03-Jul-19 4:57 PM View: | Johnson Kenneth Erland See Remarks | Xeris Pharmaceuticals Inc (XERS) | 01-Jul-19 | Grant | 174 | $9.72 | $1,691.28 | 5% 3.25K to 3.42K | (2%) |
| 03-Jul-19 4:58 PM View: | Hecht Beth See Remarks | Xeris Pharmaceuticals Inc (XERS) | 01-Jul-19 | Grant | 1,124 | $9.72 | $10,925.30 | 40% 2.8K to 3.93K | (2%) |
